70 filings
8-K
CNSP
Cns Pharmaceuticals Inc
14 Jun 24
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
5:25pm
8-K
CNSP
Cns Pharmaceuticals Inc
5 Jun 24
CNS Pharmaceuticals Announces Reverse Stock Split
5:00pm
8-K
CNSP
Cns Pharmaceuticals Inc
16 May 24
Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure
10:56am
8-K
CNSP
Cns Pharmaceuticals Inc
7 May 24
Other Events
5:00pm
8-K
CNSP
Cns Pharmaceuticals Inc
3 May 24
Departure of Directors or Certain Officers
4:26pm
8-K
o3mbe5f2
12 Apr 24
Regulation FD Disclosure
6:37pm
8-K
2mf0jxahju
1 Apr 24
Berubicin study enrollment completed; Topline data expected in first half of 2025
5:01pm
8-K
rv31nm598yocm27bgc
27 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:15pm
8-K
najqhv
21 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
7syguddfl8kcb1wlx
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
8-K
pj24hx uu4y
23 Jan 24
Departure of Directors or Certain Officers
4:01pm
8-K
u4o22zyoiamhdh 8o
21 Dec 23
Regulation FD Disclosure
9:15am
8-K
6vv7i
18 Dec 23
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy
8:36am
8-K
do3 s4st0
15 Nov 23
Results of Operations and Financial Condition
8:00am
8-K
y2k jrudh2
18 Oct 23
Regulation FD Disclosure
9:00am
8-K
9c86p4hep3tp4yjtfl
17 Oct 23
Entry into a Material Definitive Agreement
8:00am
8-K
ivf4laln
18 Sep 23
Submission of Matters to a Vote of Security Holders
7:51pm
8-K
51f1kwi0
18 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:25pm
8-K
xxaa0iiri lr
15 Aug 23
Amendments to Articles of Incorporation or Bylaws
8:30am
8-K
gtudhh
14 Aug 23
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Continued rapid pace of enrollment with ~75% of expected patients now enrolled
9:25am